With cachexia, the muscles in your body will waste away regardless of how much you eat. The condition causes severe weight loss. (Photo Credit: Dr P. Marazzi/Science Source) Cachexia (aka “wasting ...

Cancer cachexia is a complex metabolic syndrome characterized by the ongoing loss of skeletal muscle mass, with or without fat loss, that cannot be reversed entirely by conventional nutritional ...

Los Angeles, CA – August 14, 2025 – The Terasaki Institute for Biomedical Innovation announces a significant advancement in addressing the fight against cancer-associated cachexia (CAC), a ...

Available now as an early preview in Copilot Labs, this feature layers real‑time facial expressions and non‑verbal cues onto Copilot's voice interactions. The goal is to make conversations with ...

Cachexia in older SCLC patients leads to inferior survival rates and increased treatment complications, such as dose reductions and incomplete chemotherapy courses. Patients with cachexia had ...

The investigational drug ponsegromab — which inhibits growth differentiation factor 15 (GDF-15), a cytokine elevated in cancer cachexia — increases weight, appetite, and physical activity in patients ...

Christina Roffe is an Anime Features Writer from the United States. She has experience writing on games on all platforms, including PC, Nintendo, Xbox, and PlayStation. She is especially knowledgeable ...

Maintaining good health and well-being is crucial for how well patients respond to cancer treatments. Unfortunately, cachexia, or involuntary weight loss, is a major concern for many individuals with ...

Please provide your email address to receive an email when new articles are posted on . Patients with cancer cachexia assigned ponsegromab gained significantly more weight than those assigned placebo.

A nationwide clinical trial shows positive results for cancer patients with this common wasting syndrome. Researchers discovered a drug that safely and effectively helped cancer patients when they ...

Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at ...